AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24193155
Drug: Infliximab 5
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 5 mg/kg induction infusions at weeks 0, 2, and 6
Trial: 18489775
Drug: Probiotic (Lactobacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic (Lactobacillus casei rhamnosus) administered at 10^9 colony-forming units twice daily from day 3 to discharge
Trial: 1768431
Drug: DOM gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOM gel
Trial: 1768431
Drug: Ointments
RxNorm normalized name: Cod-liver oil ointments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointments
Trial: 1768431
Drug: Creams
RxNorm normalized name: ostomy, skin fillers, protective creams & sprays
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creams
Trial: 1768431
Drug: Gels
RxNorm normalized name: Gelsolin
DrugBank: Recombinant human plasma gelsolin (DB15746)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gels
Trial: 21789590
Drug: G‐Bond (GC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐Bond (GC Corp., Japan) with Gradia resin composite
Trial: 11429344
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (initial dose of 10 mg/kg and infusion of 1 mg/kg/h)
Trial: 10937295
Drug: Oral decoding
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral decoding of words and pseudowords
Trial: 8452273
Drug: Conventional spontaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional spontaneous inhalation induction technique using 4.5% sevoflurane in nitrous oxide and oxygen
Trial: 21707252
Drug: Self-administered coping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered coping planning intervention
Trial: 20629867
Drug: Carbon dioxide
RxNorm normalized name: Carbon Dioxide
DrugBank: Carbon dioxide (DB09157)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbon dioxide (CO(2)) treatment (0% at 96 h, 60% at 48 h, and 60% at 96 h)
Trial: 20629867
Drug: Ozone (O(3))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone (O(3)) treatment (0 and 175 ppm for 48 h)
Trial: 15844692
Drug: OACA (omeprazole‐amoxicillin‐clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OACA (omeprazole‐amoxicillin‐clarithromycin + aspirin)
Trial: 15844692
Drug: OAC (omeprazole‐amoxicillin‐clarithromycin)
RxNorm normalized name: AMOXICILLIN/OMEPRAZOLE/RIFABUTIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC (omeprazole‐amoxicillin‐clarithromycin)
Trial: 12433016
Drug: Nurse-administered educational
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-administered educational and behavioral intervention
Trial: 12433016
Drug: Standard-treatment (education)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-treatment (education) control group
Trial: 10069685
Drug: Short-acting nifedipine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting nifedipine, 20 mg
Trial: 7628131
Drug: simvastatin 10
RxNorm normalized name: simvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin 10 mg PO QPM
Trial: 7628131
Drug: simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin 20 mg PO QAM
Trial: 7628131
Drug: simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin 20 mg PO QPM
Trial: 26558544
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily (q.d.) lopinavir/ritonavir
Trial: 26558544
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily (b.i.d.) lopinavir/ritonavir
Trial: 23646932
Drug: ICG-augmented diode
RxNorm normalized name: ICG-136
DrugBank: ICG-136 (DB17343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICG-augmented diode laser treatment (ICG+DL) with λem = 810 nm, 60-110 J cm(‐2), 48-87-ms pulse duration, 6-mm spot size; total ICG dose 4 mg kg(‐1)
Trial: 23646932
Drug: Nd:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nd:YAG laser treatment with λem = 1064 nm, 160-240 J cm(‐2), 65-ms pulse duration, 5-mm spot size
Trial: 15194018
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of 10/10 mg ezetimibe + simvastatin
Trial: 15194018
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of 10/80 mg ezetimibe + simvastatin
Trial: 9568167
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of G‐CSF and GM‐CSF at 10 mcg/kg/day (2.5 or 5.0 mcg/kg twice per day)
Trial: 9568167
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with G‐CSF or GM‐CSF at 5 mcg/kg/day
Trial: 9568167
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with G‐CSF or GM‐CSF at 10 mcg/kg/day
Trial: 8041179
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E supplementation (300 mg dl-alpha-tocopherol 3 times daily for 4 weeks)
Trial: 31820131
Drug: Modified-release (MR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-release (MR) drug product with a proposed change in dissolution specification; specific dosage and duration not available.
Trial: 31820131
Drug: Hypothetical formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothetical formulation with 0% of drug dissolved in 2 hours in in vitro dissolution test; specific dosage and duration not available.
Trial: 31820131
Drug: PBPK absorption
RxNorm normalized name: ABSORPTION BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBPK absorption model; specific dosage and duration not available.
Trial: 21921700
Drug: Indian tetravalent
RxNorm normalized name: Indian frankincense
DrugBank: Indian frankincense (DB14275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indian tetravalent vaccine (Q-Vac (TM))
Trial: 21921700
Drug: European tetravalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: European tetravalent vaccine (Tritanrix-HB (TM))
Trial: 17039460
Drug: Isomalt (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isomalt (30 g per day)
Trial: 17039460
Drug: Sucrose (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (30 g per day)
Trial: 14977341
Drug: Intravenous anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous anaesthesia with propofol-remifentanil
Trial: 7691912
Drug: Placebo transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo transdermal nicotine
Trial: 2430512
Drug: 3-day therapy
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-day therapy with nalidixic acid
Trial: 2430512
Drug: 3-day therapy
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-day therapy with trimethoprim/sulphamethoxazole
Trial: 2430512
Drug: 10-day therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-day therapy with nalidixic acid
Trial: 2430512
Drug: 10-day therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-day therapy with trimethoprim/sulphamethoxazole
Trial: 2430512
Drug: Short-term treatment
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term treatment (3-day)
Trial: 2430512
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (10-day)
Trial: 31122495
Drug: BIIB092 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIIB092 150 mg
Trial: 31122495
Drug: BIIB092 700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIIB092 700 mg
Trial: 31122495
Drug: BIIB092 2100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIIB092 2100 mg
Trial: 26494856
Drug: High-dose FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose FOLFIRI plus bevacizumab (every 2 weeks) in group 1 (UGT1A1 *1/*1)
Trial: 26494856
Drug: High-dose FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose FOLFIRI plus bevacizumab (every 2 weeks) in group 2 (UGT1A1 *1/*28)
Trial: 26494856
Drug: High-dose FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose FOLFIRI plus bevacizumab (overall population)
Trial: 24494468
Drug: Restrictive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive group (RG) with low range of ITBVI (600‐800 ml/m2)
Trial: 24494468
Drug: Liberal group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal group (LG) with normal ITBVI (800‐1000 ml/m2)
Trial: 20209995
Drug: Unbalanced crystalloid
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unbalanced crystalloid solution
Trial: 7525694
Drug: Interferon-alpha therapy
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha therapy (recombinant interferon-alpha 2a)
Trial: 3593452
Drug: Zotepine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zotepine (100 mg)
Trial: 3593452
Drug: Moclobemide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (200 mg)
Trial: 29508020
Drug: Venoplant tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venoplant tablets and Venoplant gel
Trial: 29508020
Drug: Only Venoplant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only Venoplant tablets
Trial: 20211002
Drug: Indacaterol 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol 150 microg once-daily
Trial: 18596108
Drug: l‐NMMA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l‐NMMA
Trial: 27811949
Drug: Intraileal protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraileal protein infusion (15 g over 60 min)
Trial: 27811949
Drug: Intraileal protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraileal protein infusion
Trial: 27811949
Drug: Intraduodenal protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraduodenal protein infusion
Trial: 27811949
Drug: Jejunal protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jejunal protein infusion
Trial: 21824950
Drug: Soy isoflavone
RxNorm normalized name: soy isoflavone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavone tablets, 200 mg daily
Trial: 15612958
Drug: Extrathoracic expiratory
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extrathoracic expiratory resistance (EER; 0.89 kPa/L s at a flow of 0.5 L/s)
Trial: 9550501
Drug: Aggressive lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive lipid-lowering therapy with statins
Trial: 31236643
Drug: Cocoa flavanols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa flavanols (900 mg CF)
Trial: 31236643
Drug: Placebo (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (15 mg CF)
Trial: 26556082
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment group + visual spatial attention (optokinetic stimulation and right half‐field eye patching)
Trial: 26556082
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment group (only conventional rehabilitation training)
Trial: 1269192
Drug: Intravenous acebutolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acebutolol (1 mg/kg)
Trial: 1269192
Drug: Oral acebutolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acebutolol (3 X 100 mg)
Trial: 1269192
Drug: Renal clearance
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal clearance of acebutolol (after intravenous dosing)
Trial: 18813941
Drug: 6% carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% carbohydrate electrolyte solution (CHO)
Trial: 16542576
Drug: Enoxaparin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (1 mg/kg, q12 h) before catheterization
Trial: 16542576
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH 25 mg intravenously before coronary angiography, additional 65 mg if PCI performed)
Trial: 14499421
Drug: Intravenous adenosine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous adenosine, 2 mg
Trial: 9314644
Drug: 30/70 IA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30/70 IA (insulin aspart)
Trial: 9314644
Drug: 30/70 HI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30/70 HI (human insulin)
Trial: 1549026
Drug: Liquid glucose
RxNorm normalized name: Liquid glucose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid glucose (G)
Trial: 7523736
Drug: Expectant management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expectant management with palliative therapy reserved for symptomatic or metastatic disease progression
Trial: 28107894
Drug: Heart rate
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heart rate variability biofeedback therapy (HRV-BF)
Trial: 25160533
Drug: Lutein 10
RxNorm normalized name: lutein 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein 10 mg daily for 1 year
Trial: 18420965
Drug: Recent inhaled
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recent inhaled corticosteroid usage
Trial: 1758385
Drug: Intravenous immunoglobulins
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulins (IVIG, 500 mg/kg Sandoglobulin)
Trial: 31881702
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g of walnuts per day
Trial: 28917947
Drug: High glycemic
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High glycemic load meal + caffeine capsules (3mgkg‐1 body weight)
Trial: 28917947
Drug: High glycemic
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High glycemic load meal + placebo capsules
Trial: 28917947
Drug: Low glycemic
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low glycemic load meal + placebo capsules
Trial: 26335088
Drug: Eye Movement
RxNorm normalized name: JOINT MOVEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye Movement Desensitization and Reprocessing Therapy
Trial: 18454510
Drug: Ribavirin 800
RxNorm normalized name: ribavirin 800 Dose Pack, 4 Unit Dose Packs, 14 Tablets Each
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin 800 mg/day plus peginterferon alfa‐2a 180 mug/week
Trial: 18454510
Drug: Ribavirin 400
RxNorm normalized name: ribavirin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin 400 mg/day plus peginterferon alfa‐2a 180 mug/week
Trial: 18454510
Drug: Ribavirin 800
RxNorm normalized name: ribavirin 800 Dose Pack, 4 Unit Dose Packs, 14 Tablets Each
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin 800 mg/day (group A)
Trial: 18454510
Drug: Ribavirin 400
RxNorm normalized name: ribavirin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin 400 mg/day (group B)
Trial: 16290907
Drug: peginterferon alfa-2b
RxNorm normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: peginterferon alfa-2b 1.5 microg/kg subcutaneously once weekly plus ribavirin 800-1400 mg/day for 24 weeks
Trial: 16290907
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with undetectable serum HCV-RNA at treatment week 4
Trial: 8788532
Drug: 5‐HT1a‐receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐HT1a‐receptor agonist ipsapirone (10 mg)
Trial: 6403706
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg norethindrone + 35 micrograms ethinyl estradiol
Trial: 6403706
Drug: Levonorgestrel-containing preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel-containing preparation
Trial: 6403706
Drug: Levonorgestrel preparation
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levonorgestrel preparation
Trial: 27592805
Drug: Avelumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avelumab (10 mg/kg intravenously every 2 weeks)
Trial: 28718569
Drug: 10% potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% potassium hydroxide aqueous solution applied daily to the lesions twice daily for 6 weeks
Trial: 28718569
Drug: Cryotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryotherapy with liquid nitrogen, applied weekly for 6 weeks
Trial: 22634906
Drug: Intravenous vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vitamin C (500 mg/5 cc) three times a week for 8 weeks
Trial: 20361911
Drug: Assertive community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assertive community treatment (ACT) as part of integrated care
Trial: 10472698
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg bodyweight ketamine racemate before skin incision and 10 micrograms/kg/min ketamine infusion until peritoneum closure, followed by sodium chloride 0.9% as placebo after final skin suture.
Trial: 10472698
Drug: Placebos before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos before skin incision and intraoperatively, followed by 0.5 mg/kg bodyweight ketamine after last skin suture.
Trial: 1932765
Drug: buflomedil (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: buflomedil (400 mg intravenous perfusion for 4 hours daily for 7 days)
Trial: 7044160
Drug: Co-trimoxazole (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (high daily dosage regimens)
Trial: 27428397
Drug: Faecal immunochemical
RxNorm normalized name: Enterococcus faecalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faecal immunochemical test (FIT) for nonattendees of reduced-preparation CTC
Trial: 27428397
Drug: Faecal immunochemical
RxNorm normalized name: Enterococcus faecalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faecal immunochemical test (FIT) for nonattendees of full-preparation CTC
Trial: 25201518
Drug: Single morning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single morning dose of mitotane
Trial: 25201518
Drug: No morning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No morning dose of mitotane
Trial: 22379738
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 350 mg daily for 1 month (n = 5)
Trial: 20569710
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg norethindrone/10 microg ethinyl estradiol
Trial: 17038829
Drug: YF‐VAX (licensed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YF‐VAX (licensed yellow fever 17D vaccine)
Trial: 9241098
Drug: BIS 5
RxNorm normalized name: RIXUBIS 500units Powder for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIS 5 mg
Trial: 9241098
Drug: BIS 10
RxNorm normalized name: RIXUBIS 1000units Powder for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIS 10 mg
Trial: 8106952
Drug: Periodontal dressing
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periodontal dressing with 0.2% chlorhexidine mouthwash (10 ml for 1 minute twice daily)
Trial: 8106952
Drug: No periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No periodontal dressing with 0.2% chlorhexidine mouthwash (10 ml for 1 minute twice daily)
Trial: 3307404
Drug: Weight reduction,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight reduction, exercise, diet, and glipizide therapy
Trial: 3307404
Drug: Insulin (baseline)
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin (baseline)
Trial: 19423999
Drug: Transdermal microdose
RxNorm normalized name: LANCET,MICRODOT SAFETY 28G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal microdose 17beta-estradiol (0.014 mg/d)
Trial: 19423999
Drug: Oral raloxifene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral raloxifene (60 mg/d)
Trial: 16919005
Drug: First-line bosentan
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line bosentan treatment
Trial: 3319646
Drug: Chlorthalidone 25
RxNorm normalized name: chlorthalidone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 25 mg o.d.
Trial: 27091318
Drug: NaCl (control)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl (control) 24 mg/kg